Latest News and Press Releases

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report has been added to ...

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on...

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline...

Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's offering. CD70...

Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) --...

Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...

--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100--  MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...

– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa First Phase 2 trial in hidradenitis suppurativa using the...

MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...